, Tracking Stock Market Picks
Enter Symbol:
Advaxis, Inc. (ADXS) [hlAlert]

up 201.20 %

Advaxis, Inc. (ADXS) rated Buy with price target $12 by Noble Financial

Posted on: Monday,  Feb 10, 2014  8:25 AM ET by Noble Financial

Noble Financial rated Buy Advaxis, Inc. (NASDAQ: ADXS) on 02/10/2014, when the stock price was $4.97. Since
then, Advaxis, Inc. has gained 201.21% as of 01/21/2016's recent price of $14.97.
If you would have followed this Noble Financial's recommendation on ADXS, you would have gained 201.2% of your investment in 710 days.

Advaxis, Inc. is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania (Penn), which secretes a protein sequence containing a tumor-specific antigen. This technology involves the creation of genetically engineered Listeria that stimulates the innate immune system and induces an antigen-specific immune response involving both arms of the adaptive immune system. The Company?s products in development are ADXS11-001, ADXS31-142 and ADXS31-164. The Company uses genetically engineered and attenuated Listeria monocytogenes as a therapeutic agent. The Company?s agent ADX11-001, uses a human papilloma virus (HPV) derived antigen that is present in cervical cancers.

A clear and concise focus. Identifying the emerging small or micro cap company. Recognizing the entrepreneurial character and organizational commitment of its executives and employees. Observing unstoppable drive to exploit opportunities while tackling obstacles. Understanding the company's essential products, services and technologies. Following only those who deserve our attention.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/10/2014 8:25 AM Buy
4.97 12.00
as of 10/17/2014
1 Week up  9.59 %
1 Month down  -7.76 %
3 Months up  7.22 %
1 YTD down  -40.24 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy